Tron Group Inc And Nanopharmaceutics Inc Announce Definitive Merger Agreement

Tron Group, Inc., And Nanopharmaceutics, Inc., A Privately-Held Clinical-Stage Pharmaceutical Development Company Incorporated In Florida, Announced Today The Signing Of A Definitive Agreement For The Merger Of Nano With Nanop Acquisition Corp, Inc. ("Nanop"), A Wholly-Owned Tron Subsidiary, In An All-Stock Transaction. Following Consummation Of The Merger, Tron Will Change Its Name To Nanopharmaceutics, Inc. And Will Continue To Trade On The Otc Pink Market.Details Of Proposed MergerThe Merger Was Unanimously Approved By Both Boards Of Directors Of Tron And Nano. Under The Terms Of The Agreement, In An All-Stock Transaction, Nano And Nanop Will Merge. Tron Will Issue Five Shares Of Recently Authorized And Designated Class A Preferred Stock To Nano Shareholders In Exchange For All The Issued And Outstanding Shares Of Nano. The Company Intends To File A Corporate Action With Finra In Respect Of The Aforementioned Name Change.James D. Talton, Ph.D., President And Chief Executive Officer And Controlling Shareholder Of Both Tron And Nanopharmaceutics, Has Been Appointed Chief Executive Officer, President, Secretary/Treasurer And Director Of Tron, Effective August 8, 2022. The Board Of Directors Will Initially Be Comprised Of Three Members Including Current Tron Directors, Quoc Tuan (Jacob) Nguyen And Stephen Michael Griffith. Jr., And Dr. Talton, Who Will Also Continue To Serve As An Officer And Director Of Nano. The Combined Company'S Headquarters Will Be Located In Alachua, Florida.Immediately Prior To The Merger Agreement, Tron Entered Into An Agreement To Terminate Its Common Control Relationship With Impression Vfx Inc., Including The Extinguishment Of A Convertible Note In Exchange For The Return Of Certain Assets, And The Termination Of A Service Agreement.Clinical Stage Product PipelineThe New Company

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!